NeoGenomics (NASDAQ:NEO - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $173.40 million for the quarter. Parties interested in participating in the company's conference call can do so using this link.
NeoGenomics Stock Performance
Shares of NeoGenomics stock traded up $0.51 on Friday, reaching $14.42. 962,248 shares of the stock were exchanged, compared to its average volume of 1,018,341. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. NeoGenomics has a twelve month low of $12.13 and a twelve month high of $19.11. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -23.64 and a beta of 1.23. The business has a 50 day moving average price of $15.76 and a two-hundred day moving average price of $15.62.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. Jefferies Financial Group assumed coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price target for the company. The Goldman Sachs Group cut their price objective on NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Needham & Company LLC restated a "buy" rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Friday, January 10th. Benchmark cut NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Finally, Bank of America boosted their price objective on NeoGenomics from $18.00 to $19.00 and gave the company a "neutral" rating in a research report on Friday, December 13th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, NeoGenomics presently has an average rating of "Moderate Buy" and an average target price of $20.20.
Read Our Latest Analysis on NEO
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
